Volume : 10, Issue : 10, October – 2023
Title:
STUDY THE PREVALENCE OF NON-HEMATOLOGICAL SIDE EFFECTS OF RITUXIMAB IN RIYADH, SAUDI ARABIA
Authors :
Mohammad Hadi Dawood Almotared,Dr. Saeed A. Al Qahtani, Dr. Tanveer Khan, Ali Hamad Ali Al kulayb,Hussein Ali Al kaleb
Abstract :
Background: Rituximab (RTX) therapy has been used for hematological malignancies and autoimmune diseases for a long time, and its efficacy and safety are well documented. In spite of conflicting results from clinical trials regarding the association between RTX and infections, an increased incidence of infections or toxixity has recently been reported among patients receiving RTX for lymphomas. To date, there hasn’t been any clinical experience linking RTX with different non-hematological side effects.
Objectives: To investigate the prevalence of non-hematological side effects in in patients and outpatients receiving RTX in Riyadh, Saudi Arabia.
Methods: A retrospective cross-sectional study was conducted from July 2020 to August 2021 at King Saud University Medical City (KSUMC), Riyadh, KSA. All consecutive patients who attended the KSUMC between July 2020 to August 2021 and referred with autoimmune or different types of cancer disease were included in this study.
Results: RTX was commonly prescribed for different types of malignancies and autoimmune diseases. Non-hematological adverse reaction has been evaluated up to 1 year in patients who had been treated with RTX. The most common indications for RTX were DLBCL (36%), B cell lymphoma (20.2%), non-Hodgkin’s lymphoma (NHL) (15.7%), chronic lymphocytic leukemia (10.1%), and Hodgkin’s lymphoma (7.9%). An analysis of the association between RTX and infection among patients with hematological malignancies and autoimmune disorders was done. The most frequent adverse event was infection, infusion-related reactions. Infection rate of 34.8% was observed during the study and the infected patients had glomerulonephritis (9%), hepatitis B infection (6.7%) and renal toxicity (5.6%). Study results showed that RTX was well tolerated after one or more courses. Multiple courses did not result in increased serious infections.
Conclusion: Data from this study indicate that RTX is a commonly used for autoimmune and cancers diseases with potential beneficial effects. Although RTX has a wide range of non-hematological adverse reaction, its well-tolerated therapy for autoimmune diseases. To clarify the association between RTX and infection, further research is needed.
Keywords: Rituximab, non-hematological, autoimmune, infections, Hodgkin’s lymphom
Cite This Article:
Please cite this article in press Mohammad Hadi Dawood Almotared et al, Study The Prevalence Of Non-Hematological Side Effects Of Rituximab In Riyadh, Saudi Arabia, Indo Am. J. P. Sci, 2023; 10 (10).
Number of Downloads : 10
References:
1. Aksoy, S., Harputluoglu, H., Kilickap, S., Dede, D.S., Dizdar, O., Altundag, K. and Barista, I., 2007. Rituximab-related viral infections in lymphoma patients. Leukemia & lymphoma, 48(7), pp.1307-1312.
2. Aksoy, S., Dizdar, Ö., Hayran, M. and Harputluoğlu, H., 2009. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leukemia & lymphoma, 50(3), pp.357-365.
3. Avilés, A., Nambo, M.J., Cleto, S., Neri, N. and Huerta-Guzmán, J., 2009. Rituximab and dose-dense chemotherapy in primary testicular lymphoma. Clinical Lymphoma and Myeloma, 9(5), pp.386-389.
4. Cohen, S.B., Emery, P., Greenwald, M.W., Dougados, M., Furie, R.A., Genovese, M.C., Keystone, E.C., Loveless, J.E., Burmester, G.R., Cravets, M.W. and Hessey, E.W., 2006. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks. Arthritis & Rheumatism, 54(9), pp.2793-2806.
5. Copelan, E., Pohlman, B., Rybicki, L., Kalaycio, M., Sobecks, R., Andresen, S., Dean, R., Koo, A., Chan, J., Sweetenham, J. and Bolwell, B., 2009. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin’s lymphoma. Bone marrow transplantation, 43(2), pp.101-105.
6. Cornejo, A., Bohnenblust, M., Harris, C. and Abrahamian, G.A., 2009. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation. Cancer chemotherapy and pharmacology, 64(4), pp.857-860.
7. Covelli, M., Sarzi-Puttini, P., Atzeni, F., & Macchioni, P. (2010). Safety of rituximab in rheumatoid arthritis. Reumatismo, 62(2), 101-106.
8. Edwards, J.C. and Cambridge, G., 2006. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Reviews Immunology, 6(5), pp.394-403.
9. Gellrich, S., Muche, J.M., Wilks, A., Jasch, K.C., Voit, C., Fischer, T., Audring, H. and Sterry, W., 2005. Systemic eight‐cycle anti‐CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B‐cell lymphomas–an applicational observation. British Journal of Dermatology, 153(1), pp.167-173.
10. Kasi, P.M., Tawbi, H.A., Oddis, C.V. and Kulkarni, H.S., 2012. Clinical review: Serious adverse events associated with the use of rituximab-a critical care perspective. Critical Care, 16(4), pp.1-10.
11. Keystone, E., Fleischmann, R., Emery, P., Furst, D.E., Van Vollenhoven, R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A. and Udell, J., 2007. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open‐label extension analysis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 56(12), pp.3896-3908.
12. Lenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Hiddemann, W. 2005. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Journal of Clinical Oncology, 23(9), pp.1984-1992.
13. Pescovitz, M.D., 2006. Rituximab, an anti‐cd20 monoclonal antibody: history and mechanism of action. American Journal of Transplantation, 6(5p1), pp.859-866.
14. Taylor, R.P. and Lindorfer, M.A., 2007. Drug insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis. Nature Clinical Practice Rheumatology, 3(2), pp.86-95.
15. Uchida, J., Lee, Y., Hasegawa, M., Liang, Y., Bradney, A., Oliver, J.A., Bowen, K., Steeber, D.A., Haas, K.M., Poe, J.C. and Tedder, T.F., 2004. Mouse CD20 expression and function. International immunology, 16(1), pp.119-129.
16. Weiner, G.J., 2010, April. Rituximab: mechanism of action. In Seminars in hematology (Vol. 47, No. 2, pp. 115-123). WB Saunders.
17. Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., Pohlman, B.L., Bartlett, N.L., Wiseman, G.A., Padre, N. and Grillo-López, A.J., 2002. Randomized controlled trial of yttrium-90–labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Journal of clinical oncology, 20(10), pp.2453-2463..